Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
Francis Hong, chairman of Taiwan Medical and Biotech Industry Association (TMBIA), takes a moment during the 2019 Medical Taiwan and Taiwan Medical Components & Manufacturing Expo (MCMEX) in Taipei to share…
Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned provider to a healthcare partner. Wu goes on to offer…
Today Su, CEO of Golden Biotechnology, introduces the innovative biotech developing a revolutionary botanical drug derived from the Taiwanese fungus Antrodia Camphorata. The company’s drug, Hocena®, has already received several…
Barry Lam, founder and chairman of Quanta Computer, shares the story of how he built the company into one of the world’s leading electronics and IT manufacturers. Lam then sheds…
With the USA and China locked in a trade war, China’s near neighbour Taiwan – with its strong scientific and technology base, political security and economic reliability – may stand…
Professor Shih-Hua Lin, president of Taiwan’s National Defense Medical Center, shares an overview of the academic and research environment of the institute as well as its role in cultivating the…
Scott Li, deputy director of H Spectrum, a biotech and talent incubator within the Foxconn group, explains the organization’s history and unique role in supporting Foxconn’s transition into healthcare. Li…
William Foreman, president of AmCham Taipei, describes the attractiveness and challenges of Taiwan’s business landscape and the implications of US-China relations on the island. Foreman goes on to highlight the…
Leo Liu, president of GeneReach Biotechnology Corp, shares the story of the diagnostics startup and explains his strategy to transition the company from a leading animal health point-of-care device manufacturer…
Susan Hsu, managing director of Taiwanese data-driven CRO StatPlus, speaks about the key trends impacting Taiwan’s clinical trial environment and goes on to share her views on the increasing attractiveness…
Tony Chung, CEO of Instant NanoBiosensors explains the potential of their fibre-optic biosensor technology – FOPPR, and the commercialization strategy for their light-sensing biomarker analyzer INB-D200. He also highlights Taiwan’s…
Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory and maturation trends in the region and shares his…
See our Cookie Privacy Policy Here